Sissel Hauge

  • Scientist; Ph.D
 

Publications 2024

Rødland GE, Temelie M, Eek Mariampillai A, Hauge S, Gilbert A, Chevalier F, Savu DI, Syljuåsen RG (2024)
Potential Benefits of Combining Proton or Carbon Ion Therapy with DNA Damage Repair Inhibitors
Cells, 13 (12)
DOI 10.3390/cells13121058, PubMed 38920686

Publications 2023

Eek Mariampillai A, Hauge S, Kongsrud K, Syljuåsen RG (2023)
Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases
Front Immunol, 14, 1138920
DOI 10.3389/fimmu.2023.1138920, PubMed 37346039

Publications 2022

Eek Mariampillai A, Hauge S, Øynebråten I, Rødland GE, Corthay A, Syljuåsen RG (2022)
Caspase activation counteracts interferon signaling after G2 checkpoint abrogation by ATR inhibition in irradiated human cancer cells
Front Oncol, 12, 981332
DOI 10.3389/fonc.2022.981332, PubMed 36387237

Publications 2021

Hauge S, Eek Mariampillai A, Rødland GE, Bay LTE, Landsverk HB, Syljuåsen RG (2021)
Expanding roles of cell cycle checkpoint inhibitors in radiation oncology
Int J Radiat Biol, 99 (6), 941-950
DOI 10.1080/09553002.2021.1913529, PubMed 33877959

Rødland GE, Hauge S, Hasvold G, Bay LTE, Raabe TTH, Joel M, Syljuåsen RG (2021)
Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
Cancers (Basel), 13 (15)
DOI 10.3390/cancers13153790, PubMed 34359691

Publications 2019

Hauge S, Macurek L, Syljuåsen RG (2019)
p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775
Cell Cycle, 18 (8), 834-847
DOI 10.1080/15384101.2019.1593649, PubMed 30943845

Publications 2017

Hauge S, Naucke C, Hasvold G, Joel M, Rødland GE, Juzenas P, Stokke T, Syljuåsen RG (2017)
Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading
Oncotarget, 8 (7), 10966-10979
DOI 10.18632/oncotarget.14089, PubMed 28030798

Publications 2016

Hasvold G, Lund-Andersen C, Lando M, Patzke S, Hauge S, Suo Z, Lyng H, Syljuåsen RG (2016)
Hypoxia-induced alterations of G2 checkpoint regulators
Mol Oncol, 10 (5), 764-73
DOI 10.1016/j.molonc.2015.12.015, PubMed 26791779

Publications 2015

Syljuåsen RG, Hasvold G, Hauge S, Helland Å (2015)
Targeting lung cancer through inhibition of checkpoint kinases
Front Genet, 6, 70
DOI 10.3389/fgene.2015.00070, PubMed 25774168